Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women
Authors:
- 9 September 2015
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 37 (2) , 2183-2191
Abstract
The purpose of this study was to evaluate HE4, CA125, progesterone (Prog), and estradiol (E2) for differentiating pelvic masses in postmenopausal women and aimed to build a multi-marker model which may improve the diagnostic value. HE4, CA125, Prog, and E2 were detected in 57 benign pelvic masses (BPM) and 92 epithelial ovarian cancer (EOC) patients. A total of 66.66 % of the BPM and EOC serum samples were used for building the differentiation model, and the remaining 33.33 % of the BPM and EOC serum samples were used for validation of the differentiation model. After comparing by Z score statistics, HE4 + CA125 + E2 model was chosen as the best multi-marker model. In the training group, the area under curve of the HE4 + CA125 + E2 model was 0.97 (0.93, 1.00), sensitivities of the model for distinguishing BPM from EOC, from early EOC, and from advanced EOC were 90.16, 86.21, and 95.65 %; specificities were 92.11, 92.11, and 92.11 %. In the validation group, sensitivities of HE4 + CA125 + E2 model for distinguishing BPM from EOC, from early EOC, and from advanced EOC were 96.77, 100.00, and 87.50 %, specificities were 84.21, 100.00, and 84.21 %. The multi-marker model showed significant improvement when compared to CA125 or HE4, and it might be an effective pelvic mass differentiation method.Keywords
This publication has 50 references indexed in Scilit:
- Usefulness of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian tumorsArchives of Gynecology and Obstetrics, 2013
- Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: Correlation with pathological outcomeGynecologic Oncology, 2013
- The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic massGynecologic Oncology, 2013
- Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic massGynecologic Oncology, 2012
- The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesisGynecologic Oncology, 2012
- Potential Role of HE4 in Multimodal Screening for Epithelial Ovarian CancerJNCI: Journal of the National Cancer Institute, 2011
- HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy AlgorithmBritish Journal of Cancer, 2011
- Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic massAmerican Journal of Obstetrics and Gynecology, 2010
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- Methoxychlor and Estradiol Induce Oxidative Stress DNA Damage in the Mouse Ovarian Surface EpitheliumToxicological Sciences, 2008